Dr. Stanley Schwartz talks about addressing the epidemic of not only diabetes but the growing numbers of prediabetes patients. He reviews the current policy situation and then talks about how he proceeds in his practice with prediabetes patients. He points out that several studies have shown that adding certain medications early on to a patient’s regimen can delay the onset of diabetes. He comments that if a patient is not able to lower their blood sugars through diet and exercise, he has no hesitation in prescribing 1, 2, or even 3 medications to help them, and notes that, “I think that is where we have to go given the epidemic we are in.”…
More videos in this series with Dr. Schwartz:
- Stanley Schwartz, MD, FACP, FACE: Introduction, ADA 2014
- A New Way of Classifying Diabetes – The Beta-Cell Centric Approach
- Picking the Right Drugs for the Right Patients
- Positive Effects of More Aggressive Treatment
- Why Sulfonylureas Should No Longer Be Used
- How Do You Determine Beta Cell Function?
- Next Steps for a “Beta-Cell-Centric” Approach
Stanley Schwartz, MD, has been awarded the honor of being a TOP DOC by Philadelphia Magazine many times over the years, including 2009, 2010 and 2011 for the treatment of diabetes and metabolic syndrome. For over 30 years, Dr. Schwartz was an Associate Professor at the University of Pennsylvania, most recently directing the Diabetes Program at the Philadelphia Heart Institute. Dr. Stanley Schwartz is a new Affiliate of the Main Line Health System, and an Emeritus Associate Professor of Medicine at the University of Pennsylvania, currently in a private practice in Ardmore, Pa. Dr. Schwartz received his MD in 1973 from the University of Chicago in Chicago, Illinois. He then completed his residency at the University of Pennsylvania, followed by a fellowship in endocrinology and metabolism at the University of Chicago.
Dr. Schwartz serves on the following Advisory Boards: Eli Lilly, Inc.; Amylin Pharmaceuticals; Takeda; Janssen; sanofi-aventis; and Santarus
He is also part of the following speaker’s bureaus: Merck; Eli Lilly; Amylin Pharmaceuticals; Takeda; Santarus; BMS; Astra-Zeneca; and Novo Novartis.
Diabetes In Control is honored to also have Dr. Schwartz on our Advisory Board as well as a frequent contributor to our newsletters. You can find all of Dr. Schwartz’s Diabetes In Control articles here.